Breaking News Instant updates and real-time market news.

INCY

Incyte

$97.83

3.05 (3.22%)

, MRK

Merck

$62.77

0.11 (0.18%)

08:52
10/10/16
10/10
08:52
10/10/16
08:52

Incyte treatment looking 'promising,' says JMP Securities

After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

INCY

Incyte

$97.83

3.05 (3.22%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 10

    Oct

  • 25

    Oct

  • 06

    Nov

INCY Incyte
$97.83

3.05 (3.22%)

10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/07/16
BMOC
10/07/16
NO CHANGE
Target $121
BMOC
Outperform
Incyte price target raised to $121 from $100 at BMO Capital
BMO Capital analyst Ian Somaiya raised his price target for Incyte to $121 citing an increased probability of success for epacadostat with Keytruda in metastatic melanoma following today's data. The analyst raised his probability and success to 80% from 50% and keeps an Outperform rating on Incyte.
MRK Merck
$62.77

0.11 (0.18%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.

TODAY'S FREE FLY STORIES

NVS

Novartis

$86.73

0.08 (0.09%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Hot Stocks
Novartis granted FDA priority review for Kymriah »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Feb

  • 16

    Feb

  • 23

    Apr

  • 17

    May

SKX

Skechers

$37.91

-0.64 (-1.66%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Recommendations
Skechers analyst commentary  »

Skechers price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$100.69

-0.18 (-0.18%)

05:36
01/17/18
01/17
05:36
01/17/18
05:36
Hot Stocks
Walmart launches opioid disposal solution »

In an effort to help curb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

BLL

Ball Corp.

$38.39

0.49 (1.29%)

05:35
01/17/18
01/17
05:35
01/17/18
05:35
Upgrade
Ball Corp. rating change  »

Ball Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

PBYI

Puma Biotechnology

$90.85

-8.4 (-8.46%)

05:34
01/17/18
01/17
05:34
01/17/18
05:34
Recommendations
Puma Biotechnology analyst commentary  »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

$19.50

-0.2 (-1.02%)

05:30
01/17/18
01/17
05:30
01/17/18
05:30
Earnings
Adtran reports Q4 adj. EPS 5c, consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

PSTG

Pure Storage

$16.16

-0.31 (-1.88%)

05:27
01/17/18
01/17
05:27
01/17/18
05:27
Upgrade
Pure Storage rating change  »

Pure Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

PSDO

Presidio

$17.74

-0.96 (-5.13%)

05:25
01/17/18
01/17
05:25
01/17/18
05:25
Downgrade
Presidio rating change  »

Presidio downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNPR

Juniper

$28.61

-0.28 (-0.97%)

05:24
01/17/18
01/17
05:24
01/17/18
05:24
Downgrade
Juniper rating change  »

Juniper downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

IDTI

Integrated Device

$31.75

-0.54 (-1.67%)

, MRVL

Marvell

$23.58

-0.26 (-1.09%)

05:22
01/17/18
01/17
05:22
01/17/18
05:22
Upgrade
Integrated Device, Marvell rating change  »

Integrated Device…

IDTI

Integrated Device

$31.75

-0.54 (-1.67%)

MRVL

Marvell

$23.58

-0.26 (-1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

WWR

Westwater Resources

$1.01

-0.0449 (-4.26%)

05:20
01/17/18
01/17
05:20
01/17/18
05:20
Hot Stocks
Westwater Resources confirms receipt of $1.5M from Laramide, provides update »

Westwater Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$163.85

0.71 (0.44%)

, AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

05:20
01/17/18
01/17
05:20
01/17/18
05:20
Upgrade
IBM, Amazon.com, Microsoft rating change  »

IBM upgraded to…

IBM

IBM

$163.85

0.71 (0.44%)

AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

MSFT

Microsoft

$88.35

-1.25 (-1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

  • 18

    Mar

HPQ

HP Inc.

$22.88

-0.04 (-0.17%)

05:15
01/17/18
01/17
05:15
01/17/18
05:15
Downgrade
HP Inc. rating change  »

HP Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

WPZ

Williams Partners

$43.01

-0.18 (-0.42%)

05:14
01/17/18
01/17
05:14
01/17/18
05:14
Downgrade
Williams Partners rating change  »

Williams Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

$32.59

-0.62 (-1.87%)

05:14
01/17/18
01/17
05:14
01/17/18
05:14
Downgrade
Williams rating change  »

Williams downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPGYF

Whitecap Resources

$7.69

0.0258 (0.34%)

05:13
01/17/18
01/17
05:13
01/17/18
05:13
Upgrade
Whitecap Resources rating change  »

Whitecap Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

05:11
01/17/18
01/17
05:11
01/17/18
05:11
Downgrade
Western Gas Partners rating change  »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

WGP

Western Gas Equity

$41.76

-0.36 (-0.85%)

05:11
01/17/18
01/17
05:11
01/17/18
05:11
Downgrade
Western Gas Equity rating change  »

Western Gas Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VLP

Valero Energy Partners

$46.58

-0.11 (-0.24%)

05:11
01/17/18
01/17
05:11
01/17/18
05:11
Downgrade
Valero Energy Partners rating change  »

Valero Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

TRGP

Targa Resources

$50.75

-0.69 (-1.34%)

05:10
01/17/18
01/17
05:10
01/17/18
05:10
Upgrade
Targa Resources rating change  »

Targa Resources upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

PAGP

Plains GP Holdings

$23.41

-0.73 (-3.02%)

05:09
01/17/18
01/17
05:09
01/17/18
05:09
Downgrade
Plains GP Holdings rating change  »

Plains GP Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

PAA

Plains All American

$22.90

-1.06 (-4.42%)

05:09
01/17/18
01/17
05:09
01/17/18
05:09
Downgrade
Plains All American rating change  »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 07

    Feb

PSXP

Phillips 66 Partners

$55.73

0.58 (1.05%)

05:09
01/17/18
01/17
05:09
01/17/18
05:09
Downgrade
Phillips 66 Partners rating change  »

Phillips 66 Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

OKE

Oneok

$58.80

0.13 (0.22%)

05:08
01/17/18
01/17
05:08
01/17/18
05:08
Upgrade
Oneok rating change  »

Oneok upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$38.28

-0.5 (-1.29%)

05:07
01/17/18
01/17
05:07
01/17/18
05:07
Downgrade
MPLX rating change  »

MPLX downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.